

Remarks

Notice of Non-Compliant Amendment

Recitation of the status of previously canceled claims 1-22 has been provided. Applicants respectfully submit that a complete listing of all the claims is present.

Amendments to the Claims

Entry of the above amendments is respectfully requested. Claim 24 has been amended by addition of the definition of variables B, E and R<sup>4</sup>. Support for this amendment is in original claims 1-2 and in the specification as filed. Applicants submit that no new matter has been introduced by these amendments.

Election/Restriction Requirement under 35 U.S.C §121

In response to the Election/Restriction Requirement under 35 U.S.C §121 Applicants elect the following species: (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or a pharmaceutically acceptable salt thereof. The election of species made above reads on claims 23-26. It is submitted that Applicants have fully complied with the Examiner's restriction requirement. Early examination and allowance of the claims is respectfully requested.

Conclusion

Applicants believe that, in view of the amendments to the claims and the remarks made above, this application is in condition for allowance. Entry of the amendments to the claims and reconsideration and allowance of claims 23-26, as amended, is respectfully requested.

Date: 14 November 2006

Pfizer Inc  
Patent Department, MS: 8260-1611  
Eastern Point Road  
Groton, CT 06340  
Phone: (860) 715-6645  
Fax: (860) 441-5221

By: / John A. Wichtowski /

John A. Wichtowski  
Attorney for Applicant(s)  
Registration No. 48,032